Evaluation of lymphocyte infiltrate composition in triple-negative mammary carcinomas and its association with clinical-pathologic and demographic data.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 1131-1131
Author(s):  
Geraldine Eltz Lima ◽  
Felipe D'Almeida Costa ◽  
Alexandre Andre Balieiro Anastacio da Costa ◽  
José A. Rinck ◽  
Andrea Paiva G. Guimaraes ◽  
...  
Keyword(s):  
Triple Negative ◽  
Demographic Data ◽  
Mammary Carcinomas ◽  
Lymphocyte Infiltrate

Treatment effectiveness in advanced breast cancer patients in Italy: Ten years experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11573-e11573
Author(s):  
Sandro Barni ◽  
Ilaria Vallini ◽  
Marta Bonotto ◽  
Antonella Brunello ◽  
Monica Indelli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Prognostic Factors ◽  
Soft Tissue ◽  
Triple Negative ◽  
Demographic Data ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Luminal B ◽  
Oncology Unit

e11573 Background: Several studies suggest that newer therapies can improve survival in MBC, but a different impact on overall survival (OS) is observed according to histology, extension of disease and prognostic factors. This survey was performed for evaluate Italian experience in cancer treatment in the last ten years. Methods: We collected data from 13 Italian Medical Oncology Unit; we registered all consecutive patients (pts) with breast cancer who have developed metastasis between 2000 and 2008. Demographic data, pathological characteristics and treatment were reported. OS was calculated from time of recurrence and stratified according to biological characteristics and to recurrence date. Results: 1542 pts was suitable for analysis; median age 61,7 (range 22-94); MBC at diagnosis 21,8%. Site of disease recurrence: bone 26,2%, visceral 25,4%, bone and visceral 20,7%, soft tissue 11,5%, soft tissue and visceral 8,4%, bone and soft tissue 7,8%. Molecolar classification: luminal A 66,3%, luminal B 14,5%, triple negative 11,5%, HER2+ like 7,7%. Pts received a median of 2 lines of chemotherapy (range 0-10) and 1 line of hormonal therapy (range 0-7); 22,5% received biological drugs. 15,5% of metastatic pts were enrolled in clinical trials. After a median follow up of 7.1 years 84,1% pts died (1297/1542 pts) and median OS was 2,7 years (range 2,6-2,9). We did not observe difference in OS for pts divided into 3 groups according to recurrence date (2000-2002, 2003-2005, 2006-2008). A longer median OS was observed in luminal B (3,8 years) versus luminal A and HER2+ like (2,8 years) and triple negative disease (1,2 years). Conclusions: Our survey describe a large number of MBC pts treated in 13 Italian Oncology Unit. OS analysis did not show significant differences according to recurrence date, but for different prognostic factors. OS data are superimposable to literature ones, showing a good transfer from clinical trials to clinical practice.

scholarly journals Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer

2014 ◽  
Vol 10 (1) ◽  
Author(s):  
Diego Caliari ◽  
Valentina Zappulli ◽  
Roberta Rasotto ◽  
Barbara Cardazzo ◽  
Federica Frassineti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Mammary Carcinomas ◽  
Comparative Model

scholarly journals PD-1 and PD-L1 are diagnostic biomarkers and PD-L1 a promising therapeutic target in HER2-positive and triple negative normal-like feline mammary carcinoma subtypes

2020 ◽  
Author(s):  
Catarina Nascimento ◽  
Ana Catarina Urbano ◽  
Andreia Gameiro ◽  
João Ferreira ◽  
Jorge Correia ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Mammary Carcinoma ◽  
Triple Negative ◽  
Strong Positive Correlation ◽  
Her2 Positive ◽  
Diagnostic Biomarkers ◽  
Mammary Carcinomas ◽  
Tumor Subtypes ◽  
Promising Therapeutic Target ◽  
Feline Mammary Carcinoma

AbstractTumor microenvironment has gained great relevance due to its ability to regulate distinct checkpoints mediators, orchestrating tumor progression. In order to understand the role of the PD- 1/PD-L1 axis in cats with mammary carcinoma, serum PD-1 and PD-L1 levels were compared with healthy controls and with serum CTLA-4 and TNF-α levels. PD-1 and PD-L1 expression was evaluated in TILs and cancer cells, as the presence of somatic mutations. Results showed that serum PD-1 and PD-L1 levels were significantly higher in cats with HER2-positive (p=0.017; p=0.032) and triple negative (TN) normal-like mammary carcinomas (p=0.004; p=0.015). Besides, cats presenting these tumor subtypes showed a strong positive correlation between serum PD-1, PD-L1, CTLA-4 and TNF-α levels. In tumors, PD-L1 expression in cancer cells was significantly higher in HER2-positive samples than in TN normal-like tumors (p=0.010), as the percentage of PD-L1-positive TILs (p=0.038). Results from the PD-L1 gene sequencing identified two heterozygous mutations in exon 4 (A245T, 3.8%; V252M, 42.3%) and one in exon 5 (T267S, 3.8%). In summary, results support that serum PD-1 and PD-L1 levels can be used as diagnostic biomarkers of HER2-positive and TN normal-like feline mammary carcinomas and suggest that the development of monoclonal antibodies may be a good therapeutic strategy.

Identification of Triple-negative and Basal-like Canine Mammary Carcinomas using Four Basal Markers

2013 ◽  
Vol 148 (4) ◽  
pp. 298-306 ◽  
Author(s):  
N.H. Kim ◽  
H.Y. Lim ◽  
K.S. Im ◽  
J.H. Kim ◽  
J.-H. Sur
Keyword(s):  
Triple Negative ◽  
Mammary Carcinomas

scholarly journals Immunohistochemical Profile of Molecular Markers of Mammary Carcinomas in Libreville

2021 ◽  
Vol 2 (2) ◽  
pp. 55-62
Author(s):  
Barthélemy Mabika ◽  
Nicole Josiane Andeme ◽  
Sidonie Solange Nguizi Ogoula ◽  
Guy Joseph Lémamy
Keyword(s):  
Molecular Markers ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Progesterone Receptors ◽  
Molecular Classification ◽  
Breast Cancers ◽  
Luminal A ◽  
Mammary Carcinomas ◽  
Luminal B ◽  
Immunohistochemical Profile

To establish the immunohistochemical profile of the molecular markers of free-ranging breast carcinomas. Descriptive retrospective study over 3 years from July 2014 to September 2017. The tumour samples came from the Anatomical Pathology Laboratories of the Omar Bongo Ondimba Army Instruction Hospital and the University of Health Sciences. In total, the records of 60 patients with histologically proven breast carcinoma with the immunohistochemical study were included in the study. The following molecular markers, hormone receptors (estrogen receptors, progesterone receptors), the HER2/Neu oncogene, and the Ki67 cell proliferation marker, was identified using the Immunohistochemistry technique.The average age was 47.6 years, with extremes of 15 and 69 years. Depending on the location, the right breast was most commonly affected (50%). Histologically, there was a predominance of infiltrating ductal carcinomas (66.6%) and a majority SBR III grade (50%). This study revealed an immunohistochemical profile of positive hormone receptors: ERs + (13.3%); PRs + (8.3%) and a Ki67 profile positive in 10% of tumors. The molecular classification into 4 subtypes (Luminal A, Luminal B, HER2 and Triple Negative) places the Luminal A group in the first rank (33.3%) followed by the Luminal B (15%), Triple Negative (11.6%) and HER2 (8.3%). The present work is the first study reporting the immunohistochemical profile of molecular markers of mammary carcinomas in Gabon. It would be necessary to continue this study on a larger and wider cohort throughout Gabon because the knowledge of the immunohistochemical profile gives an indication of the origin of breast cancers and allows to consider better management of patients by a targeted therapy to avoid unnecessary toxic effects resulting from ineffective treatment.

Abstract LB-46: Spontaneous canine mammary carcinomas as a model of human triple-negative breast cancer

2011 ◽  
Author(s):  
Jerome Abadie ◽  
Delphine Loussouarn ◽  
Catherine Ibisch ◽  
Frederique Nguyen ◽  
Natascha Rieder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Mammary Carcinomas

scholarly journals Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer

Tumor Biology ◽  
2020 ◽  
Vol 42 (1) ◽  
pp. 101042831990105 ◽  
Author(s):  
Elie Dagher ◽  
Laura Simbault ◽  
Jérôme Abadie ◽  
Delphine Loussouarn ◽  
Mario Campone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Regulatory T Cell ◽  
Triple Negative ◽  
Growth Factor Receptor ◽  
Breast Cancers ◽  
Mammary Carcinomas ◽  
Epidermal Growth

Feline invasive mammary carcinomas are characterized by their high clinical aggressiveness, rare expression of hormone receptors, and pathological resemblance to human breast cancer, especially triple-negative breast cancer (negative to estrogen receptor, progesterone receptor, and epidermal growth factor receptor type 2). Recent gene expression studies of triple-negative breast cancers have highlighted their heterogeneity and the importance of immune responses in their biology and prognostic assessment. Indeed, regulatory T cells may play a crucial role in producing an immune-suppressed microenvironment, notably in triple-negative breast cancers. Feline invasive mammary carcinomas arise spontaneously in immune-competent animals, in which we hypothesized that the immune tumor microenvironment also plays a role. The aims of this study were to determine the quantity and prognostic value of forkhead box protein P3-positive peritumoral and intratumoral regulatory T cells in feline invasive mammary carcinomas, and to identify an immune-suppressed subgroup of triple-negative basal-like feline invasive mammary carcinomas. One hundred and eighty female cats with feline invasive mammary carcinomas, treated by surgery only, with 2-year follow-up post-mastectomy, were included in this study. Forkhead box protein P3, estrogen receptor, progesterone receptor, Ki-67, epidermal growth factor receptor type 2, and cytokeratin 14 expression were assessed by automated immunohistochemistry. Peritumoral regulatory T cells were over 300 times more abundant than intratumoral regulatory T cells in feline invasive mammary carcinomas. Peritumoral and intratumoral regulatory T cells were associated with shorter disease-free interval and overall survival in both triple-negative (ER–, PR–, HER2–, N = 123 out of 180) and luminal (ER+ and/or PR+, N = 57) feline invasive mammary carcinomas. In feline triple-negative basal-like (CK14+) mammary carcinomas, a regulatory T-cell–enriched subgroup was associated with significantly poorer disease-free interval, overall survival, and cancer-specific survival than regulatory T-cell-poor triple-negative basal-like feline invasive mammary carcinomas. High regulatory T-cell numbers had strong and negative prognostic value in feline invasive mammary carcinomas, especially in the triple-negative basal-like subgroup, which might contain a “basal-like immune-suppressed” subtype, as described in triple-negative breast cancer. Cats with feline invasive mammary carcinomas may thus be interesting spontaneous animal models to investigate new strategies of cancer immunotherapy in an immune-suppressed tumor microenvironment.

Sign in / Sign up

Export Citation Format

Share Document